Table 2. Outcome of initial and repeated hormonal treatment.
| Characteristics | Initial treatment group | Repeated treatment group | p-value | |
|---|---|---|---|---|
| CR rate | AEH | 98.5% (64/65) | 96.4% (27/28) | n.s. |
| G1 | 90.7% (88/97) | 98.1% (53/54) | 0.097 | |
| Median MTP (mo) | AEH | 4.9 (1.9–15.0) | 5.1 (2.7–16.8) | n.s. |
| G1 | 6.1 (2.5–28.8) | 6.6 (3.7–17.3) | n.s. | |
| Median TTD (mo) | AEH | 2.7 (0.1–18.8) | 3.8 (0.9–15.9) | n.s. |
| G1 | 4.5 (0.6–24.9) | 4.4 (0.7–15.1) | n.s. | |
| Recurrence rate | AEH | 42.1% (27/64) | 66.6% (18/27) | 0.024 |
| G1 | 63.2% (55/87) | 81.1% (43/53) | 0.036 | |
| Pregnancy rate | AEH | 29.2% (19/65) | 11.1% (3/27) | 0.107 |
| G1 | 22.7% (20/88) | 20.8% (11/53) | n.s. |
AEH, atypical endometrial hyperplasia; CR, complete response; G1, grade 1 endometrioid carcinoma; MTP, medroxyprogesterone acetate treatment period; n.s., not significant; TTD, time-to-tumor disappearance.